In Vitro & In Vivo Diagnostic Substances · DE · CIK 949858
Develops and commercializes cytisinicline to address nicotine dependence and the vaping epidemic
Comparable business profile · signals at a glance
Coverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗